Get Premium to unlock powerful stock data
NAS:CVAC (Germany)  
CureVac NV logo

CureVac NV

$ 13.87 -0.07 (-0.5%) 08:08 PM EST
P/E:
At Loss
P/B:
3.51
Market Cap:
$ 2.60B
Enterprise V:
$ 1.95B
Volume:
480.01K
Avg Vol (2M):
718.59K
Also Trade In:
Volume:
480.01K
Market Cap $:
2.60B
PE Ratio:
At Loss
Avg Vol (2-Month):
718.59K
Enterprise Value $:
1.95B
PB Ratio:
3.51
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%

Business Description

CureVac NV
NAICS : 541714 SIC : 2833
Friedrich-Miescher-Strasse 15, Tubingen, BW, DEU, 72076
Description
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.
Name Current Vs Industry Vs History
Cash-To-Debt 16.3
Equity-to-Asset 0.66
Debt-to-Equity 0.06
Debt-to-EBITDA -0.13
Piotroski F-Score N/A/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 2.28
Distress
Grey
Safe
Beneish M-Score 0
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 36.72
9-Day RSI 37.38
14-Day RSI 38.91
6-1 Month Momentum % -42.62
12-1 Month Momentum % -71.32

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 3.32
Quick Ratio 3.21
Cash Ratio 2.79
Days Inventory 101.35
Days Sales Outstanding 39.08
Days Payable 112.71

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -2.1

Financials (Next Earnings Date:2022-08-16 Est.)

CVAC's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:CVAC

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 134.924
EPS (TTM) ($) -1.982
Beta 0
Volatility % 86.56
14-Day RSI 38.91
14-Day ATR ($) 0.954917
20-Day SMA ($) 15.086
12-1 Month Momentum % -71.32
52-Week Range ($) 12.9 - 76.22
Shares Outstanding (Mil) 187.12

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 9999
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

CureVac NV Filings

Document Form Filing Date
No Filing Data

Headlines

See More